Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Dotarizine may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Dotarizine may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Dotarizine. |
| Buprenorphine | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Hydrocodone | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Magnesium sulfate | The therapeutic efficacy of Dotarizine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dotarizine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Mirtazapine | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Orphenadrine | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Pramipexole | Dotarizine may increase the sedative activities of Pramipexole. |
| Ropinirole | Dotarizine may increase the sedative activities of Ropinirole. |
| Rotigotine | Dotarizine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dotarizine. |
| Sodium oxybate | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Thalidomide | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Cimetidine | The serum concentration of Dotarizine can be increased when it is combined with Cimetidine. |
| Clopidogrel | The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Dotarizine. |
| Efavirenz | The serum concentration of Dotarizine can be decreased when it is combined with Efavirenz. |
| Melatonin | The therapeutic efficacy of Dotarizine can be decreased when used in combination with Melatonin. |
| Nafcillin | The therapeutic efficacy of Dotarizine can be decreased when used in combination with Nafcillin. |
| Nitroprusside | Dotarizine may increase the hypotensive activities of Nitroprusside. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dotarizine. |
| Dantrolene | The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Dotarizine. |
| Lithium citrate | The risk or severity of adverse effects can be increased when Dotarizine is combined with Lithium citrate. |
| Lithium carbonate | The risk or severity of adverse effects can be increased when Dotarizine is combined with Lithium carbonate. |
| Lithium hydroxide | The risk or severity of adverse effects can be increased when Dotarizine is combined with Lithium hydroxide. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Dotarizine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Dotarizine is combined with Phenindione. |
| Coumarin | The risk or severity of adverse effects can be increased when Dotarizine is combined with Coumarin. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Dotarizine is combined with Tioclomarol. |
| Warfarin | The risk or severity of adverse effects can be increased when Dotarizine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Dotarizine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Dotarizine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Dotarizine is combined with 4-hydroxycoumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Dotarizine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Dotarizine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Dotarizine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Dotarizine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Dotarizine is combined with Diphenadione. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Dotarizine is combined with (S)-Warfarin. |
| Boceprevir | The serum concentration of Dotarizine can be increased when it is combined with Boceprevir. |
| Ethanol | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Dotarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dotarizine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Dotarizine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Dotarizine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Dotarizine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Sibutramine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Dotarizine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Dotarizine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Dotarizine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Dotarizine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Dotarizine is combined with Alaproclate. |
| Ibutilide | Ibutilide may increase the arrhythmogenic activities of Dotarizine. |
| Adenosine | Adenosine may increase the arrhythmogenic activities of Dotarizine. |
| Levosimendan | Levosimendan may increase the arrhythmogenic activities of Dotarizine. |
| Procainamide | Procainamide may increase the arrhythmogenic activities of Dotarizine. |
| Tocainide | Tocainide may increase the arrhythmogenic activities of Dotarizine. |
| Flecainide | Flecainide may increase the arrhythmogenic activities of Dotarizine. |
| Encainide | Encainide may increase the arrhythmogenic activities of Dotarizine. |
| Ajmaline | Ajmaline may increase the arrhythmogenic activities of Dotarizine. |
| Aprindine | Aprindine may increase the arrhythmogenic activities of Dotarizine. |
| Azimilide | Azimilide may increase the arrhythmogenic activities of Dotarizine. |
| Tedisamil | Tedisamil may increase the arrhythmogenic activities of Dotarizine. |
| Vernakalant | Vernakalant may increase the arrhythmogenic activities of Dotarizine. |
| Carteolol | Dotarizine may increase the arrhythmogenic activities of Carteolol. |
| Metipranolol | Dotarizine may increase the arrhythmogenic activities of Metipranolol. |
| Cariporide | Dotarizine may increase the arrhythmogenic activities of Cariporide. |
| Xylometazoline | Dotarizine may increase the arrhythmogenic activities of Xylometazoline. |
| Sparteine | Dotarizine may increase the arrhythmogenic activities of Sparteine. |
| Fasudil | Dotarizine may increase the arrhythmogenic activities of Fasudil. |
| Simendan | Dotarizine may increase the arrhythmogenic activities of Simendan. |
| Spiradoline | Dotarizine may increase the arrhythmogenic activities of Spiradoline. |
| Pilsicainide | Dotarizine may increase the arrhythmogenic activities of Pilsicainide. |
| Cicletanine | Dotarizine may increase the arrhythmogenic activities of Cicletanine. |
| Cibenzoline | Dotarizine may increase the arrhythmogenic activities of Cibenzoline. |
| Nizofenone | Dotarizine may increase the arrhythmogenic activities of Nizofenone. |
| Prajmaline | Dotarizine may increase the arrhythmogenic activities of Prajmaline. |
| Tiracizine | Dotarizine may increase the arrhythmogenic activities of Tiracizine. |
| Ethacizine | Dotarizine may increase the arrhythmogenic activities of Ethacizine. |
| Lorajmine | Dotarizine may increase the arrhythmogenic activities of Lorajmine. |